[Use of fluoroquinolones in rheumatology]. 1996

B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva

The efficacy and tolerance of 3 fluoroquinolones (ciprofloxacin, pefloxacin, lomefloxacin) were studied in 157 patients with rheumatic diseases concurrent with infection-induced abnormalities. Infection cure was achieved in 123 (78.6%) patients, as evidenced by clinical, microbiological, and serological studies. The tolerance of fluoroquinolones was regarded as good, satisfactory, and poor in 114 (72.6%), 37 (23.6%), and 6 (3.8%) patients, respectively. All representative drugs of the fluoroquinolones series produced typical adverse reactions. The authors consider it expedient to make further clinical studies to test the optimal treatment regimens and to expand indications for the use of fluoroquinolones in this group of patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents

Related Publications

B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
January 2007, The Veterinary record,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
January 1996, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
January 1993, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
January 1999, Duodecim; laaketieteellinen aikakauskirja,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
February 2006, Current opinion in pediatrics,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
March 2000, The Annals of pharmacotherapy,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
October 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
April 2015, International journal of antimicrobial agents,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
January 1999, Zhonghua nei ke za zhi,
B S Belov, and S V Shubin, and V A Nasonova, and S I Soldatova, and G M Tarasova, and M M Urumova, and M A Ushakova, and L P Anan'eva
September 2006, Pediatrics,
Copied contents to your clipboard!